Europe Respiratory Therapeutic Devices Market Size

Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

The European market for therapeutic devices for the lungs is expected to grow significantly, reaching a value of $ 5.01 billion in 2025 and $ 11.064 billion in 2034. The CAGR for the forecast period is 9.2%. The increase in the number of patients with chronic obstructive pulmonary disease (COPD) and the ageing of the population will drive the demand for advanced therapeutic devices. The development of digital health solutions and smart inhalers will also enhance patient adherence and improve outcomes, driving market growth. The major companies, including Philips, GSK and ResMed, are investing heavily in R&D, forming strategic alliances and launching new products to capture market share. Recent collaborations aimed at developing connected devices, for example, highlight the industry’s focus on improving patient management and outcomes.

Regional Market Size

Regional Deep Dive

The European respiratory devices market is characterized by a high demand for products owing to the high prevalence of respiratory diseases, a large aging population, and technological advancements. In addition, the growing demand for home care solutions and the preference for portable and easy-to-use devices are driving the home care solutions market in the region. Also, the European Union’s regulatory framework encourages innovation while ensuring patient safety, which is expected to drive the market growth. Also, the integration of digital health technologies such as telemedicine and remote patient monitoring is making the market more accessible and efficient.

Europe

• The European Medicines Agency (EMA) has introduced new guidelines for the approval of combination devices, which are expected to facilitate the entry of advanced respiratory devices that integrate drug delivery with therapeutic functions.
• Companies such as Boehringer Ingelheim and AstraZeneca are investing heavily in research and development for smart inhalers, which are designed to improve medication adherence and patient outcomes, reflecting a trend towards personalized medicine.

Asia Pacific

• The Asia-Pacific region is experiencing a surge in demand for respiratory devices due to rising pollution levels and increasing awareness of respiratory health, with companies like OMRON and Philips expanding their market presence.
• Government initiatives in countries like India and China are focusing on improving healthcare infrastructure, which is expected to enhance access to respiratory therapeutic devices in rural areas.

Latin America

• Latin America is witnessing an increase in respiratory diseases due to urbanization and lifestyle changes, prompting companies like GSK and Novartis to expand their product offerings in the region.
• Government health programs in Brazil and Mexico are focusing on improving access to respiratory care, which is expected to drive the adoption of therapeutic devices.

North America

• The FDA has recently expedited the approval process for several innovative respiratory devices, allowing companies like ResMed and Philips to bring new products to market more quickly, enhancing competition and consumer choice.
• Telehealth initiatives have gained momentum, with organizations like the American Lung Association promoting remote patient monitoring solutions, which are expected to increase the adoption of respiratory devices in home settings.

Middle East And Africa

• In the Middle East, the growing prevalence of chronic respiratory diseases is prompting healthcare providers to adopt advanced therapeutic devices, with companies like Medtronic entering the market to meet this demand.
• Regulatory bodies in Africa are beginning to implement stricter guidelines for medical devices, which is expected to improve the quality and safety of respiratory devices available in the region.

Did You Know?

“Approximately 300 million people worldwide suffer from asthma, and the prevalence is particularly high in Europe, where it affects about 10% of the population.” — World Health Organization (WHO)

Segmental Market Size

The European respiratory therapeutic devices market is growing steadily, mainly due to the growing number of respiratory diseases and the aging of the population. The demand for devices to manage chronic diseases such as asthma and COPD is increasing, as well as the favorable regulatory environment for medical devices. The technological development, especially smart inhalers and portable oxygen systems, is also important for improving patient compliance and improving outcomes. At present, the market is in a mature stage of development, and Philips and ResMed are the leading companies in the field of advanced respiratory devices in Europe. The main application environment is in the home, hospital and outpatient clinic, and nebulizers and CPAP devices are widely used. However, the pandemic of influenza A (H1N1) and other macro-economic factors have increased the attention to the respiratory system, and governments have increased their investment in medical equipment and telehealth. The Internet of Things (IoT) technology will play an important role in the development of respiratory devices, and real-time monitoring and treatment plans will be provided.

Future Outlook

In Europe the market for pulmonary therapeutic devices is expected to grow significantly from 2025 to 2034, from $ 5 billion to $ 11.0 billion, at a CAGR of 9.2%. The growing number of patients with obstructive pulmonary diseases and asthma is expected to reach more than 50 million in Europe by 2034. Health systems are increasingly focusing on pulmonary health, and the demand for advanced therapeutic devices will continue to grow, resulting in improved patient outcomes and quality of life. And technological innovations, such as digital health solutions and telemedicine, are expected to drive market growth. Smart inhalers and connected devices will help patients adhere to treatment and monitor their condition in real time, thereby improving the effectiveness of treatment. Supportive policies, such as the introduction of reimbursement and support for the development of new devices, will also drive the market. In addition, the trend of preventive medicine and the rise of personalized medicine will also play an important role in shaping the future development of the European pulmonary therapeutic device market.